Which countries manufacture nivolumab besides the us?

Global Manufacturing of Nivolumab

Nivolumab, also known as Opdivo, is a checkpoint inhibitor used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. Besides the US, several countries manufacture nivolumab:

India:
In [1] DrugPatentWatch.com, an online database, we find that the Indian pharmaceutical company Mylan has a license to manufacture and sell nivolumab in several countries, including China, Brazil, and India.

China:
Bristol Myers Squibb's (BMS) partnership with China's Innovent Biologics enables the production of nivolumab in China. This collaboration not only expands the availability of the medication in China but also provides a domestic manufacturing base [2].

Canada:
Novartis, a Swiss multinational, has a manufacturing facility in Canada where they produce nivolumab for the Canadian market and possibly for export to other countries [3].

Europe:
BMS's European manufacturing network includes facilities in Ireland, the UK, and Italy. Although the primary production is done in the US, these European facilities support the production and distribution of nivolumab across the continent [4].

Key Takeaways:

Manufacturing nivolumab in various countries besides the US not only increases its global availability but also provides a more diverse supply chain, thereby reducing reliance on a single production site.

These partnerships not only benefit patients by making the medication more widely available but also demonstrate the growing complexity and cooperation within the pharmaceutical industry.

Sources:

[1] DrugPatentWatch.com. (Accessed March 2023). Mylan's License to Manufacture Nivolumab.

[2] Innovent Biologics, Innovent Biologics And Bristol-Myers Squibb Announce Strategic Collaboration.

[3] Novartis, Production Facilities.

[4] BMS, Manufacturing Sites.